Abstract
RESULTS: SSC expressed low level of MHC I, no CD80, CD86 or MHC II. SSC suppressed allogeneic T cell proliferation, IFNgamma production and inhibited stimulatory function of dendritic cells in MLR. In vivo, SSC and BM cells co-infused at 4 time-points (4xBM SSC) significantly delayed GVHD onset compared to 4xBM (p 0.0016) and enhanced donor hematopoietic cell engraftment. The 4xBM SSC group had significant prolongation in flap survival, compared to the 4xBM (p 0.0007) or to the CsA group (p 0.0006). Histopathologically, flap skin and muscle of 4xBM SSC recipients revealed less mononuclear cell infiltration and normal tissue architecture. Two animals (2xBM SSC and 1xBM SSC groups) recovered from GVHD and flaps were accepted. One rat (2xBM group) showed wound healing (POD 56) after initial rejection.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
